Burning Rock Biotech (BNR) Q3 2024 earnings summary

Executive summary

• Achieved commercial breakeven (excluding R&D) in 3Q24, marking a significant milestone under new industry conditions.

• Q3 2024 revenue reached RMB128.7 million, up 1% year-over-year, with in-hospital business growth offsetting central lab declines.

• Net loss narrowed to RMB35.7 million from RMB175.0 million year-over-year, reflecting significant cost reductions.

• Strategic partnership with MGI Tech and NMPA approval for a co-developed NGS-based CDx for lung cancer marked key business milestones.

• Strong cash position expected to fund operations for the next three years.

Financial highlights

• 3Q24 revenue was RMB 128.7 million, up 1% year-over-year but down 5% sequentially.

• Non-GAAP gross profit for 3Q24 was RMB 97.8 million, up 3% year-over-year but down 4% sequentially.

• Non-GAAP gross margin reached 76.0% in Q3 2024, up from 74.5% a year earlier.

• Total operating expenses in 3Q24 dropped 51% year-over-year and 37% sequentially to RMB 130.5 million.

• Net operating cash outflow reduced to RMB 30.3 million in Q3 2024.

Outlook and guidance

• Selling expense ratio expected to remain below 40% going forward.

• Additional G&A cost savings anticipated into 2024.

• Management highlighted ongoing transition to in-hospital testing and continued focus on operational efficiency.

• Disciplined R&D investment to continue, with commercial operations (excluding R&D) profitable.

• Forward-looking statements caution about risks and uncertainties due to market and operating conditions.